| Literature DB >> 17697356 |
Abstract
BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that bind mRNA target transcripts and repress gene expression. They have been implicated in multiple diseases, such as cancer, but the mechanisms of this involvement are not well understood. Given the complexity and degree of interactions between miRNAs and target genes, understanding how miRNAs achieve their specificity is important to understanding miRNA function and identifying their role in disease.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17697356 PMCID: PMC2374997 DOI: 10.1186/gb-2007-8-8-r166
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
Figure 1Analysis of the relationship between shorter 3' UTRs and increased repression. The error bars for observed and expected data are based on the distribution of RE values and the distribution of the permutated data, respectively. (a) Shorter 3' UTRs in target genes are more strongly repressed by their predicted cognate miRNAs. (b) The expected RE values (computed using permutation testing) show minimal deviation from 1.0, representing a lack of repression. (c) This trend is increasingly exaggerated when subsets of miRNAs containing larger expression ratios between groups A and B are used, especially in 3' UTRs shorter than 200 bp. (d) The same trend of increased repression in shorter 3' UTRs is observed using a different target prediction algorithm, rna22.
Figure 2Analysis of site and gene features that affect miRNA repression. The observed values are shown in black; the expected values (computed using permutation testing) are shown in gray. The error bars for observed and expected data are based on the distribution of RE values and the distribution of the permutated data, respectively. (a) Target genes with more binding sites are more strongly repressed. (b) Pairs of binding sites targeted by the same miRNA that are between 16 and 30 bp apart (by start positions) have significantly increased repression (asterisks shown for emphasis). (c) Genes that have multiple pairs of extensively overlapping sites, defined to be two binding sites responsive to the same miRNA whose start positions are within 10 bp of each other, have increased repression.
Figure 3Frequency of pairs of binding sites targeted by the same miRNAs separated by a given distance. The distance between a pair of binding sites is calculated from the 5' ends of the target sites relative to the mRNA. A disproportionate number of binding site pairs are within 10 bp of each other.
Figure 4CTG repeat-binding miRNAs and their repression of pairs of extensively overlapping sites. (a) A diagram showing how a region of NM_173354 containing seven CTG repeats can result in six binding site seeds (CTGCTG) and five pairs of extensively overlapping sites (pairs of binding sites 3 bp apart). (b) Seven miRNAs containing CAG-rich seed regions that are predicted to bind to CTG repeats. Only hsa-miR-214 has mismatches in the seed region. (c) Number of overlapping binding sites versus relative expression for seven CTG repeat-binding miRNAs. In general, as the number of pairs of extensively overlapping sites increases, the degree of repression increases. In particular, mirs-107, -103, and -15a show a strong correlation. (d) Decreased relative expression of wild-type DMPK with respect to seven CTG repeat-binding miRNAs suggests repression of mutated DMPK by miRNAs could play a role in DM1. Targets with no overlapping pairs of sites served as control and showed no overall repression.
The 50 genes targeted by the most miRNAs using PicTar target predictions
| Gene symbol | No. of miRNAs targeting gene | Refseq ID | Entrez gene description |
| ATXN1 | 65 | NM_000332 | Ataxin 1 |
| CPEB4 | 63 | NM_030627 | Cytoplasmic polyadenylation element binding protein 4 |
| MECP2 | 62 | NM_004992 | Methyl cpg binding protein 2 (Rett syndrome) |
| OTUD4 | 61 | NM_199324 | OTU domain containing 4 |
| OGT | 60 | NM_003605 | O-linked N-acetylglucosamine (glcnac) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) |
| PURB | 60 | NM_033224 | Purine-rich element binding protein B |
| EIF2C1 | 58 | NM_012199 | Eukaryotic translation initiation factor 2C, 1 |
| CPEB2 | 54 | NM_182485 | Cytoplasmic polyadenylation element binding protein 2 |
| PLAG1 | 53 | NM_002655 | Pleiomorphic adenoma gene 1 |
| NOVA1 | 53 | NM_006489 | Neuro-oncological ventral antigen 1 |
| DYRK1A | 52 | NM_101395 | Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A |
| HIC2 | 49 | NM_015094 | Hypermethylated in cancer 2 |
| RAP2C | 49 | NM_021183 | RAP2C, member of RAS oncogene family |
| TRPS1 | 48 | NM_014112 | Trichorhinophalangeal syndrome I |
| NARG1 | 48 | NM_057175 | NMDA receptor regulated 1 |
| NLK | 47 | NM_016231 | Nemo like kinase |
| BACH2 | 47 | NM_021813 | BTB and CNC homology 1, basic leucine zipper transcription factor 2 |
| KLF12 | 47 | NM_007249 | Kruppel-like factor 12 |
| QKI | 46 | NM_206853 | Quaking homolog, KH domain RNA binding (mouse) |
| CPEB3 | 46 | NM_014912 | Cytoplasmic polyadenylation element binding protein 3 |
| USP6 | 46 | NM_004505 | Ubiquitin specific peptidase 6 (Tre-2 oncogene) |
| YTHDF3 | 45 | NM_152758 | YTH domain family, member 3 |
| ESRRG | 45 | NM_206594 | Estrogen-related receptor gamma |
| CCND2 | 44 | NM_001759 | Cyclin D2 |
| CCNJ | 44 | NM_019084 | Cyclin J |
| RSBN1 | 44 | NM_018364 | Round spermatid basic protein 1 |
| NFAT5 | 44 | NM_173214 | Nuclear factor of activated T-cells 5, tonicity-responsive |
| CAMTA1 | 44 | NM_015215 | Calmodulin binding transcription activator 1 |
| CNOT6 | 43 | NM_015455 | CCR4-NOT transcription complex, subunit 6 |
| E2F3 | 43 | NM_001949 | E2F transcription factor 3 |
| CHES1 | 43 | NM_005197 | Checkpoint suppressor 1 |
| ANK2 | 43 | NM_001148 | Ankyrin 2, neuronal |
| MAP3K3 | 43 | NM_002401 | Mitogen-activated protein kinase kinase kinase 3 |
| DNAJC13 | 42 | NM_015268 | Dnaj (Hsp40) homolog, subfamily C, member 13 |
| MNT | 42 | NM_020310 | MAX binding protein |
| PPARGC1A | 41 | NM_013261 | Peroxisome proliferative activated receptor, gamma, coactivator 1, alpha |
| TRIM2 | 41 | NM_015271 | Tripartite motif-containing 2 |
| ZNF238 | 41 | NM_006352 | Zinc finger protein 238 |
| PAFAH1B1 | 41 | NM_000430 | Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45 kDa |
| HMGA2 | 41 | NM_003483 | High mobility group AT-hook 2 |
| FNDC3B | 41 | NM_022763 | Fibronectin type III domain containing 3B |
| FBXO33 | 40 | NM_203301 | F-box protein 33 |
| STC1 | 40 | NM_003155 | Stanniocalcin 1 |
| CPD | 40 | NM_001304 | Carboxypeptidase D |
| CHD9 | 40 | NM_025134 | Chromodomain helicase DNA binding protein 9 |
| KIAA0261 | 40 | NM_015045 | Kiaa0261 |
| RNF38 | 40 | NM_022781 | Ring finger protein 38 |
| BAZ2A | 39 | NM_013449 | Bromodomain adjacent to zinc finger domain, 2A |
| CBFA2T3 | 39 | NM_175931 | Core-binding factor, runt domain, alpha subunit 2; translocated to, 3 |
| FNDC3A | 39 | NM_014923 | Fibronectin type III domain containing 3A |
Figure 5Abundance and functional enrichment of genes targeted by many distinct miRNAs. (a) The observed number of genes targeted by many miRNAs is dramatically greater than the expected number for all three algorithms. The threshold for the number of miRNAs to be considered highly targeted is defined to be one standard deviation more than the average number of miRNAs predicted to target a gene. (b) A large proportion of genes targeted by many miRNAs are transcriptional regulators and nuclear genes, but this enrichment decreases as the number of miRNAs is reduced. Genes involved in ion transporters do not show this trend. In (b-d), asterisks denote P < 0.01. (c) Enrichment, instead of proportion (as before), is shown of transcriptional regulators and nuclear genes for highly targeted genes, with the same enrichment for highly targeted genes. The expected enrichment for a random set of genes targeted by any number of miRNAs is 1.0 (that is, no enrichment), shown by the dotted line. (d) The enrichment of transcriptional regulators and nuclear genes among highly targeted genes remains after controlling for 3' UTR length.
Gene Ontology categories overrepresented among the 165 genes targeted by more than 30 miRNAs
| Category | Term | Count | % | |
| Biological Process 5 | Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism | 51 | 30.91 | 5.55E-12 |
| Biological Process 4 | Homophilic cell adhesion | 15 | 9.09 | 1.82E-11 |
| Biological Process 5 | Transcription | 51 | 30.91 | 1.96E-11 |
| Biological Process 4 | Regulation of cellular metabolism | 54 | 32.73 | 9.26E-11 |
| Biological Process 3 | Nervous system development | 23 | 13.94 | 1.49E-10 |
| Biological Process 3 | Regulation of metabolism | 54 | 32.73 | 1.71E-10 |
| Biological Process 3 | Regulation of cellular physiological process | 61 | 36.97 | 2.46E-09 |
| Biological Process 3 | Cell-cell adhesion | 15 | 9.09 | 1.10E-08 |
| Biological Process 4 | Nucleobase, nucleoside, nucleotide and nucleic acid metabolism | 56 | 33.94 | 5.15E-06 |
| Cellular Component 3 | Nucleus | 72 | 43.64 | 1.31E-08 |
| Cellular Component 3 | Intracellular membrane-bound organelle | 79 | 47.88 | 2.91E-04 |
| Molecular Function 3 | DNA binding | 49 | 29.70 | 1.12E-08 |
| Molecular Function 4 | Transcription factor activity | 30 | 18.18 | 8.45E-08 |
| Molecular Function 3 | Metal ion binding | 64 | 38.79 | 1.87E-07 |
| Molecular Function 3 | Cation binding | 60 | 36.36 | 6.06E-07 |
| Molecular Function 5 | Zinc ion binding | 35 | 21.21 | 6.33E-05 |
| Molecular Function 4 | Calcium ion binding | 23 | 13.94 | 6.74E-05 |
| Molecular Function 4 | Sequence-specific DNA binding | 14 | 8.48 | 4.49E-04 |
| Molecular Function 5 | Transcription corepressor activity | 6 | 3.64 | 1.12E-03 |
| Molecular Function 3 | Transcription corepressor activity | 6 | 3.64 | 1.69E-03 |
| Molecular Function 5 | Calcium-transporting atpase activity | 3 | 1.82 | 6.05E-03 |
Significant terms (P < 0.01) from levels 3-5 of each ontology are shown.
Figure 6Downregulated expression and enrichment of cancer genes among highly targeted genes. (a) In a comparison of highly targeted genes (n > 20) versus less targeted genes (1 ≤ n ≤ 5) in normal tissue samples [46], 121 out of 158 samples exhibited decreased expression among highly targeted genes (P = 1 × 10-11). (b) Out of 58 NCI60 cancer cell line samples, 58 exhibited decreased expression among highly targeted genes (P = 7 × 10-18). (c) Highly targeted genes are enriched for cancer genes, with cancer genes targeted by >30 miRNAs having the most enrichment. In (c,d), asterisks denote P < 0.01 and crosses denote P < 0.05.(d) This enrichment for cancer genes remains after removing transcriptional regulators, which are prevalent among cancer genes and, as shown earlier, overrepresented among highly targeted genes.